A Study to Find the Best Dose of Fezolinetant to Treat Hot Flashes in Women Going Through Menopause

Hot Flashes Clinical Trial

— Starlight  

Official title:

A Randomized, Placebo-Controlled, Double-Blind, Phase 2 Study to Select the Optimal Dose(s) of Fezolinetant in Women Suffering From Vasomotor Symptoms (Hot Flashes) Associated With Menopause in Japan

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05034042
• Other study ID #: 2693-CL-0206
• Secondary ID: jRCT2031210334
• Status: Completed
• Phase: Phase 2
• Start date: November 17, 2021
• Est. completion date: December 23, 2022

Study information

• Verified date: November 2023
• Source: Astellas Pharma Inc
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is for menopausal women who have hot flashes. Menopause, a normal part of life, is the time after a woman's last period. Hot flashes often occur during menopause. They can disrupt a woman's daily life. This study will take place in Japan. This study will provide more information on a potential new treatment, called fezolinetant. The treatments in this study are fezolinetant or a placebo. In this study, a placebo is a dummy treatment that looks like fezolinetant but does not have any medicine in it. The study will compare fezolinetant with the placebo to find the best dose of fezolinetant to reduce the number and severity of hot flashes. Women that want to take part in the study will be given an electronic handheld device to track their hot flashes. In the last 10 days before their next clinic visit, the women will record information about their hot flashes. Women will be picked for 1 of 3 treatments (lower or higher dose of fezolinetant, or placebo) by chance alone. Women who take part in the study will take 2 tablets every day for 12 weeks. Treatment will be double-blinded. That means that the women in the study and the study doctors will not know who takes which of the study medicines (lower or higher dose of fezolinetant, or placebo). The women will continue recording information about their hot flashes on the electronic device. They will also use another device to answer questions about how hot flashes affect their daily life. During the study, the women will visit their study clinic several times for a check-up. This will happen during weeks 2, 4, 8, 12 and 15. At the check-up, they will be asked if they have any medical problems. Other checks will include some blood samples taken for laboratory tests. At some check-ups, the women will have a physical exam, an ECG to check their heart rhythm, and their vital signs checked (pulse rate, temperature and blood pressure). At the first visit and in week 15, women who have a uterus will also have a test called a transvaginal ultrasound. A probe is gently placed inside the vagina. Sound waves will create a picture of the organs in the pelvis. This will allow the study doctor to look more closely at the uterus and surrounding organs. The last check-up (at week 15) will be 3 weeks after they take their last tablets of study medicine (lower or higher dose of fezolinetant or placebo).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 147
• Est. completion date: December 23, 2022
• Est. primary completion date: November 11, 2022
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 40 Years to 65 Years

Eligibility

Inclusion Criteria:

• Subject has a body mass index = 16 kg/m^2 and = 38 kg/m^2 at screening visit.
• Subject must be seeking treatment or relief for vasomotor symptoms (VMS) associated with menopause and confirmed as menopausal per 1 of the following criteria at the screening visit:

For post-menopausal subjects:

• Spontaneous amenorrhea for = 12 consecutive months
• Spontaneous amenorrhea for = 6 months with biochemical criteria of menopause (follicle-stimulating hormone [FSH] > 40 IU/L); or
• Having had bilateral oophorectomy = 6 weeks prior to the screening visit (with or without hysterectomy)

For peri-menopausal subjects:

• Skipped menstrual period with amenorrhea for = 60 days but < 6 consecutive months with biochemical criteria of peri-menopause (FSH > 25 IU/L); or
• Spontaneous amenorrhea for = 6 months but < 12 consecutive months with biochemical criteria of peri-menopause (FSH > 25 IU/L and = 40 IU/L)
• Within the 10 days prior to randomization, subject must have a minimum average of 7 mild, moderate and severe hot flashes (VMS) per day.
• Subject is not pregnant and at least 1 of the following conditions apply:
• Not a woman of childbearing potential (WOCBP)
• WOCBP who agrees to follow the contraceptive guidance from the time of informed consent through at least 21 days after the final study treatment administration
• Subject must agree not to breastfeed starting at screening and throughout the study period and for 21 days after the final study treatment administration.
• Subject must not donate ova starting at first dose of investigational product (IP) and throughout the study period and for 21 days after the final study treatment administration.
• Subject is in good general health as determined on the basis of medical history and general physical examination, including a bimanual clinical pelvic examination and clinical breast examination devoid of relevant clinical findings, performed at the screening visit; hematology and biochemistry parameters, pulse rate and/or blood pressure, and electrocardiogram (ECG) within the reference range for the population studied, or showing no clinically relevant deviations.
• Subject has documentation of a normal/negative or no clinically significant abnormal findings on breast imaging (obtained at screening or within the prior 12 months of screening). Appropriate documentation includes a written report or an electronic report indicating normal/negative or no clinically significant abnormal findings on breast imaging.
• Subject is willing to undergo a transvaginal ultrasound (TVU) to evaluate the uterus and ovaries at screening and week 12 (end of treatment), and for subjects who are withdrawn from the study prior to completion, a TVU at the early discontinuation visit. This is not required for subjects who have had a partial (supra-cervical) or full hysterectomy.
• Subject is willing to undergo endometrial biopsy at any time during the study in the case of uterine bleeding. This is not required for subjects who have had a partial (supra-cervical) or full hysterectomy and for peri-menopausal subjects in case of menstrual bleeding.
• Subject has documentation of a normal or not clinically significant abnormal Pap test (or equivalent cervical cytology) within the previous 12 months of screening or at screening. This is not required for subjects who have had a full trachelectomy.
• Subject has a negative urine pregnancy test at screening. Urine pregnancy test is not required for female subjects who are assessed as post-menopausal status.
• Subject has negative serology panel (i.e. negative hepatitis B surface [HBs] antigen) and negative hepatitis C virus [HCV] antibody) at screening.
• Subject agrees not to participate in another interventional study while participating in the present study.

Exclusion Criteria:

• Subject uses a prohibited therapy (strong or moderate cytochrome P450 1A2 [CYP1A2] inhibitors, hormone replacement therapy [HRT], hormonal contraceptive or any treatment for VMS [prescription, over the counter, or herbal/Chinese medicine]) or is not willing to wash out and discontinue use of such drugs for the full duration of study conduct or it is not medically appropriate to discontinue such drugs for the duration of the study.
• Subject has known substance abuse or alcohol addiction within 6 months of screening.
• Subject has a history of a malignant tumor except for non-metastatic basal cell carcinoma of the skin.
• Subject has uncontrolled hypertension.
• Subject has a history of severe allergy, hypersensitivity, or intolerance to drugs in general, including the IP and any of its excipients.
• For subjects with a uterus: Subject has an unacceptable result from the TVU assessment at screening, (i.e., full length of endometrial cavity cannot be visualized or presence of a clinically significant abnormal finding).
• Subject has a history of an undiagnosed uterine bleeding within the previous 6 months of screening.
• Subject has a history of seizures or other convulsive disorders.
• Subject has a medical condition or chronic disease (including history of neurological [including cognitive], hepatic, renal, cardiovascular, gastrointestinal, pulmonary [e.g., moderate asthma], endocrine, or gynecological disease) or malignancy that could confound interpretation of the study outcome.
• Subject has active liver disease, jaundice, or elevated liver aminotransferases (alanine aminotransferase [ALT] or aspartate aminotransferase [AST]), elevated total or direct bilirubin, elevated international normalized ratio (INR), or elevated alkaline phosphatase (ALP) at screening. Subject with mildly elevated ALT or AST up to < 1.5 × the upper limit of normal (ULN) can be enrolled if total and direct bilirubin are normal. Subject with mildly elevated ALP (up to < 1.5 × ULN) can be enrolled if cholestatic liver disease is excluded and no cause other than fatty liver is diagnosed. Subject with Gilbert's syndrome with elevated total bilirubin (TBL) may be enrolled as long as direct bilirubin (DBL), hemoglobin and reticulocytes are normal.
• Subject has creatinine > 1.5 × ULN; or estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease formula = 59 mL/min/1.73 m^2 at screening visit.
• Subject has a previous positive test for the human immunodeficiency virus.
• Subject has a history of suicide attempt or suicidal behavior within the prior to 12 months of study enrollment or has suicidal ideation within the prior to 12 months of study enrollment (a response of "yes" to question 4 or 5 on the suicidal ideation portion of the Columbia Suicide Severity Rating Scale [C-SSRS]), or who is at significant risk to commit suicide at screening and at visit 2.
• Subject has had previous exposure with fezolinetant.
• Subject has received an IP within 28 days or 5 half-lives, whichever is longer, prior to screening.
• Subject is unable or unwilling to complete the study procedures.
• Subject has any condition which makes the subject unsuitable for study participation.
• Subject or relative is the investigator or other site staff directly involved in the conduct of the study.
• Subject is an employee of the sponsor, contract research organizations (CROs) or site management organizations (SMOs).
• Present or previous history of participation in a study of the IP.

Related Conditions & MeSH terms

• Hot Flashes

Intervention

Drug:
• Fezolinetant
oral
• Placebo
oral

Locations

Country	Name	City	State
Japan	Hamada Hospital	Chiyoda-ku	Tokyo
Japan	Ginza Yoshida Clinic	Chuo-Ku	Tokyo
Japan	Medical Corporation Asbo Tokyo Asbo Clinic	Chuo-ku	Tokyo
Japan	Mori Ladies Clinic	Fukuoka-shi	Fukuoka
Japan	SANO Women's Clinic	Fukuoka-shi	Fukuoka
Japan	Medical Corp. SEIKOUKAI New Medical Research System Clinic	Hachioji-shi	Tokyo
Japan	Unoki Clinic	Kagoshima-shi	Kagoshima
Japan	Yoshinaga Women's Clinic	Kagoshima-shi	Kagoshima
Japan	Japan Organization of Occupational Health and Safety Kyushu Rosai Hospital	Kitakyusyu-shi	Fukuoka
Japan	Kurashiki Medical Clinic	Kurashiki-shi	Okayama
Japan	Kurobe City Hospital	Kurobe-shi	Toyama
Japan	Omi Medical Center, Social Medical Corporation Seikoukai	Kusatsu-shi	Shiga
Japan	Kyoto City Hospital	Kyoto-shi	Kyoto
Japan	Juno Vesta Clinic Hatta	Matsudo-shi	Chiba
Japan	Social Medical Care Corporation Hosei-kai Marunouchi Hospital	Matsumoto-shi	Nagano
Japan	Toranomon Womens Clinic	Minato-ku	Tokyo
Japan	Yokokura Clinic	Minato-ku	Tokyo
Japan	Shimamura Memorial Hospital	Nerima-ku	Tokyo
Japan	Yukawa Women's Clinic	Nishitokyo-shi	Tokyo
Japan	Omihachiman Community Medical Center	Omihachiman-shi	Shiga
Japan	GyNet Medical Corporation Minamimorimachi Ladies' Clinic	Osaka-shi	Osaka
Japan	Nomura Clinic Namba	Osaka-shi	Osaka
Japan	Sophia Ladies Clinic	Sagamihara-shi	Kanagawa
Japan	Maruyama Memorial General Hospital	Saitama-shi	Saitama
Japan	Ena Odori Clinic	Sapporo-shi	Hokkaido
Japan	Kotoni Ladies Clinic	Sapporo-shi	Hokkaido
Japan	M's Ladies Clinic	Sapporo-shi	Hokkaido
Japan	Nishikawa Women's Health Clinic	Sapporo-shi	Hokkaido
Japan	Sapporo Medical Center, NTT East Corporation	Sapporo-shi	Hokkaido
Japan	Tonan Hospital	Sapporo-shi	Hokkaido
Japan	Chieko Yukika Lady's Clinic	Sendai-shi	Miyagi
Japan	Seijo Kinoshita Hospital	Setagaya-ku	Tokyo
Japan	Japan Community Healthcare Organization Tokuyama Central Hospital	Shunan-shi	Yamaguchi
Japan	Asahi-Clinic	Takamatsu-shi	Kagawa
Japan	jMOG Medical Corporation Tanabe Ladies' Clinic	Takatsuki-shi	Osaka
Japan	Ikebukuro Clinic	Toshima-ku	Tokyo
Japan	Ikebukuro Metropolitan Clinic	Toshima-ku	Tokyo
Japan	Japan Organization of Occupational Health and Safety Toyama Rosai Hospital	Uozu-shi	Toyama
Japan	Tawada Ladies Clinic	Yokohama-shi	Kanagawa
Japan	Women's Clinic LUNA Yokohama Motomachi	Yokohama-shi	Kanagawa

Sponsors (1)

Lead Sponsor	Collaborator
Astellas Pharma Inc

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean change from baseline in the frequency of mild, moderate and severe vasomotor symptom (VMS)	Frequency of mild, moderate or severe VMS events will be calculated as the sum of mild, moderate or severe VMS events per day.	Baseline and Week 8
Secondary	Mean change from baseline in the frequency of mild, moderate and severe VMS	Frequency of mild, moderate or severe VMS events will be calculated as the sum of mild, moderate or severe VMS events per day.	Baseline and up to Week 12
Secondary	Number of participants with Adverse Events (AEs)	An AE is any untoward medical occurrence in a subject administered an investigational product (IP), and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IP whether or not considered related to the IP.	Up to Week 15
Secondary	Change from baseline in endometrial thickness	Endometrial thickness is a measure of how thick the lining of the uterus is. Endometrial thickness will be measured by transvaginal ultrasound (TVU).	Baseline and Week 12
Secondary	Number of participants with laboratory value abnormalities and/or AEs	Number of participants with potentially clinically significant laboratory values.	Up to Week 15
Secondary	Number of participants with vital sign abnormalities and/or AEs	Number of participants with potentially clinically significant vital sign values.	Up to Week 15
Secondary	Number of participants with electrocardiogram (ECG) abnormalities and/or AEs	Number of participants with potentially clinically significant ECG values.	Up to Week 12
Secondary	Number of participants with suicidal ideation and/or behavior as assessed by Columbia-Suicide Severity Rating Scale (C-SSRS)	The Columbia-Suicide Severity Rating Scale (C-SSRS) is a clinician administered assessment tool that evaluates suicidal ideation and behavior. Number of participants that have an affirmative response provided to the 5 items for suicidal ideation (1. Wish to be dead, 2. Non-specific active suicidal thoughts, 3. Active suicidal ideation with any methods (not plan) without intent to act, 4. Active suicidal ideation with some intent to act, without specific plan, 5. Active suicidal ideation with specific plan and intent) and/or to the 5 items for suicidal behavior (1. Preparatory acts or behavior, 2. Aborted attempt, 3. Interrupted attempt, 4. Actual attempt, 5. Completed suicide) will be reported.	Up to Week 15

External Links

•   Link to plain language summary of the study on the Trial Results Summaries website.
•   Link to results and other applicable study documents on the Astellas Clinical Trials website.